Respiratory Drug Delivery VII
Respiratory Drug Delivery VII was held in Palm
Harbor at Tarpon Springs, Florida from May 14 to May 18, 2000, and
organized by Virginia
Commonwealth University School of Pharmacy. It was the seventh
in a series of international symposia concerning all aspects of
drug delivery to the lung.
Over 550 attendees
from around the world (Australia, Belgium, Canada, Denmark, Finland,
France, Germany, Italy, Japan, Portugal, Sweden, Switzerland, Taiwan,
UK and USA) gathered in Florida for an action packed week.
Academia, government, and the pharmaceutical industry were represented
at this premier meeting in the world in pharmaceutical aerosols.
The scientific program ran for four days, and individual
sessions targeted:
- Asthma in the Third Millenium
- New Therapeutic Opportunities
- Manipulating PK & PD: Effects of Molecular Structure, Formulation
and Regional Deposition
- New MDI Formulations
- Device Development: Control & Regulation
- Special Forum: Bioequivalence in Multiphase Nasal Sprays
- Progress in Drug Development
- Characterizing Aerosol Size and Deposition
- New Challenges in Aerosol Delivery Technology
The pre-prints of all podium sessions and posters were published
by Serentec Press and are also available
electronically on RDD Online.
A complete list of all of the Scientific Poster presentations can
be found in the RDD
7 Proceedings. They cover a broad selection of topics related
to pulmonary and nasal drug delivery, and each one has been peer
reviewed.
A special thanks to the sponsors
of RDD VII 2000
3M Drug Delivery Systems, Abbott Laboratories, Aeropharm
Technology, AstraZeneca, Aradigm Corporation, Battelle Pulmonary
Therapeutics, Bausch & Lomb Pharmaceuticals, Bespak, Boehringer
Ingelheim, Bristol Myers Squibb, CCL Pharmaceuticals, Chiesi Farmaceutici,
ClinTrials BioResearch, DMV International, DuPont Fluoroproducts,
Dura Pharmaceuticals, GlaxoWellcome, Hoechst Marion Roussel, Hoffman-La-Roche,
Inhale Therapeutic Systems, Inspire Pharmaceuticals, Magellan Laboratories,
Nastech, Novartis Pharma AG, Pamasol Willi Mader AG, Pathogenesis
Corporation, Primedica Corporation, Quadrant Healthcare, Solvay
Fluorides, Valois Pharm, Vectura Limited, Whitehall Robins & Wyeth
Ayerst Research
|